Published in J Antibiot (Tokyo) on June 01, 1992
Experimental evaluation of HR756, a new cephalosporin derivative: pre-clinical study. Infection (1977) 4.89
A community study of diabetes in Oxfordshire. J R Coll Gen Pract (1983) 2.88
Continuous cell lines and immune ascitic fluid pools in arbovirus detection. Res Virol (1993) 2.64
Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues. Eur J Clin Microbiol (1983) 2.45
[Surveillance of the circulation of arbovirus of medical interest in the region of eastern Senegal]. Bull Soc Pathol Exot (1993) 2.35
The children's hour: the State Children's Health Insurance Program. Health Aff (Millwood) (1998) 1.95
Ability of the T cell-replacing polyanion dextran sulfate to trigger the alternate pathway of complement activation. Eur J Immunol (1973) 1.68
Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother (1995) 1.52
[The antibacterial activity in vitro of ofloxacin in comparison with other orally administered antimicrobial substances on ampicillin-resistant clinical isolates]. Arzneimittelforschung (1984) 1.50
Isolations of West Nile and Bagaza viruses from mosquitoes (Diptera: Culicidae) in central Senegal (Ferlo). J Med Entomol (1994) 1.49
Oxidation and dehalogenation of 4-chlorophenylacetate by a two-component enzyme system from Pseudomonas sp. strain CBS3. J Bacteriol (1984) 1.47
Purification and some properties of component A of the 4-chlorophenylacetate 3,4-dioxygenase from Pseudomonas species strain CBS. J Biol Chem (1986) 1.46
DNP-antigens activate the alternate pathway of the complement system. J Immunol (1974) 1.44
Mersacidin, a new antibiotic from Bacillus. In vitro and in vivo antibacterial activity. J Antibiot (Tokyo) (1992) 1.44
The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides. Infection (1984) 1.41
Activation by some T-independent antigens and B cell mitogens of the alternative pathway of the complement system. J Immunol (1975) 1.39
Degradation of 4-chlorophenylacetic acid by a Pseudomonas species. J Bacteriol (1981) 1.32
Arbovirus surveillance from 1990 to 1995 in the Barkedji area (Ferlo) of Senegal, a possible natural focus of Rift Valley fever virus. J Med Entomol (2001) 1.27
HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum. Arzneimittelforschung (1983) 1.27
An RVF epidemic in southern Mauritania. Ann Inst Pasteur Virol (1989) 1.26
Cefodizime, an aminothiazolyl cephalosporin. IV. Influence on the immune system. J Antibiot (Tokyo) (1984) 1.25
[Microbial degradation and 4-chlorophenylacetic acid. Chemical synthesis of 3-chloro-4-hydroxy-, 4-chloro-3-hydroxy- and 4-chloro-2-hydroxyphenylacetic acid (author's transl)]. Hoppe Seylers Z Physiol Chem (1982) 1.21
Lymphocytes in the bronchoalveolar space reenter the lung tissue by means of the alveolar epithelium, migrate to regional lymph nodes, and subsequently rejoin the systemic immune system. Anat Rec (2001) 1.18
Dengue 2 outbreak in southeastern Senegal during 1990: virus isolations from mosquitoes (Diptera: Culicidae). J Med Entomol (1994) 1.13
Lues maligna, or ulceronodular syphilis, in a man infected with human immunodeficiency virus: case report and review. Clin Infect Dis (1995) 1.11
Factor D in the alternate pathway of complement activation: purification, physicochemical characterization and functional role. Immunochemistry (1974) 1.09
Formation of transmural complement pores in serum-sensitive Escherichia coli. Infect Immun (1987) 1.08
The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus. J Antimicrob Chemother (1992) 1.07
[Crimean-Congo hemorrhagic fever in Senegal. Latest data on the ecology of the CCHF virus]. Bull Soc Pathol Exot (1994) 1.05
Balhimycin, a new glycopeptide antibiotic produced by Amycolatopsis sp. Y-86,21022. Taxonomy, production, isolation and biological activity. J Antibiot (Tokyo) (1994) 1.05
Purification and some properties of component B of the 4-chlorophenylacetate 3,4-dioxygenase from Pseudomonas species strain CBS 3. J Biol Chem (1987) 1.04
The conservation of poly-A-containing RNA during the dormant state of the moss Polytrichum commune. Nucleic Acids Res (1976) 1.01
Friulimicins: novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. II. Isolation and structural characterization. J Antibiot (Tokyo) (2000) 1.01
Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother (1991) 1.00
Cefodizime, an aminothiazolylcephalosporin. II. Comparative studies on the pharmacokinetic behavior in laboratory animals. J Antibiot (Tokyo) (1984) 1.00
Analytical study of a Rift Valley fever epidemic. Res Virol (1989) 1.00
Effect of cordycepin on nucleic acid metabolism in L5178Y cells and on nucleic acid-synthesizing enzyme systems. Cancer Res (1977) 1.00
Potent antileukemic activity of the novel cytostatic agent avarone and its analogues in vitro and in vivo. Cancer Res (1985) 0.99
Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother (1995) 0.99
World pandemic of obesity: the situation in Southern African populations. Public Health (2001) 0.98
Surveillance for yellow fever virus in eastern Senegal during 1993. J Med Entomol (1996) 0.97
Endoscopic photodynamic therapy with hematoporphyrin derivative for primary treatment of gastrointestinal neoplasms in inoperable patients. Dig Dis Sci (1990) 0.95
Purification and characterization of a cephalosporinase from E. coli. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 0.95
Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice. Infection (1986) 0.95
Intestinal absorption of beta-lactam antibiotics and oligopeptides. Functional and stereospecific reconstitution of the oligopeptide transport system from rabbit small intestine. Eur J Biochem (1992) 0.94
[An enzymic method for the determination of cefotaxim in serum and urine (author's transl)]. J Clin Chem Clin Biochem (1981) 0.94
[Stability, bone healing and loss of correction after valgus realignment of the tibial head. A roentgen stereometry analysis]. Orthopade (2004) 0.94
Esmolol prevents movement and attenuates the BIS response to orotracheal intubation. Br J Anaesth (2002) 0.93
[Imaging and preoperative planning of osteotomy of tibial head osteotomy]. Orthopade (2004) 0.91
Involvement of ras p21 in neurotrophin-induced response of sensory, but not sympathetic neurons. J Cell Biol (1993) 0.90
Cefodizime, an aminothiazolylcephalosporin. V. Synthesis and structure-activity relationships in the cefodizime series. J Antibiot (Tokyo) (1987) 0.90
Chemotherapeutic properties of the new cephalosporin antibiotic HR810 in laboratory animals. Infection (1984) 0.89
Antibacterial activity of cefotaxime and other newer cephalosporins (in vitro and in vivo). J Antimicrob Chemother (1980) 0.89
HRE 664, a new parenteral penem. I. Antibacterial activity in vitro. J Antibiot (Tokyo) (1987) 0.88
Cefodizime, an aminothiazolyl cephalosporin. III. Therapeutic activity against experimentally induced pneumonia in mice. J Antibiot (Tokyo) (1984) 0.87
Intranasal oxytocin in obsessive-compulsive disorder. Psychoneuroendocrinology (1987) 0.87
The biological activity of bacteriophage DNA, prepared by the cationic detergent dilution technique. Nucleic Acids Res (1975) 0.86
Active p21Ras is sufficient for rescue of NGF-dependent rat sympathetic neurons. Neuroscience (1996) 0.86
U.S. civil rights policy and access to health care by minority Americans: implications for a changing health care system. Med Care Res Rev (2000) 0.86
Inhibition of HIV and virus replication by polysulphated polyxylan: HOE/BAY 946, a new antiviral compound. AIDS (1988) 0.86
Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients. Eur J Clin Microbiol Infect Dis (1994) 0.85
Does the new TNM classification (1997) improve prognostic stratification in gastric cancer submitted to R0 surgery? Eur J Surg Oncol (1999) 0.85
Lassa fever virus in Senegal. J Infect Dis (1988) 0.85
The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability. Infection (1982) 0.85
Cancer of the oesophagus in Africans in sub-Saharan Africa: any hopes for its control? Eur J Cancer Prev (2002) 0.85
Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro. J Antibiot (Tokyo) (1999) 0.84
Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas. Cancer Immunol Immunother (2000) 0.84